THE MCCULLOUGH REPORT Bio-Pharmaceutical complex wages war against respiratory syncytial virus
Jan 9, 2024
Dr. Peter McCullough discusses the marketing campaign against RSV and the potential risks of monoclonal antibody treatment. The podcast explores RSV classification and proteins, heart health, and immunity. There are also discussions on safety concerns of Biofortunes monoclonal antibody, vaccine pressure, and censorship issues.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Introduction
00:00 • 3min
RSV Classification, Structure, and Proteins
02:36 • 18min
Solo Performance and Heart Health
20:08 • 8min
Musical interlude and ads for COFIC's RX throat spray and the Wellness Company's Spike Support Formula
28:34 • 4min
Supporting the Body, Building Muscle, and Strengthening Immunity
32:12 • 4min
Safety Concerns and Efficacy of Biofortunes Monoclonal Antibody for RSV Prevention
36:26 • 17min
Vaccine Pressure, Censorship, and Internet Provider
53:37 • 2min
Challenges with Sending Emails and Accessing Rumble in France
55:29 • 2min